Hematoloji ve Covid-19

Sahu KK, Kumar R. Current perspective on pandemic of COVID-19 in the United States. J Fam Med Prim Care. 2020 Apr 1;9(4):1784.

Cengiz Seval G, İlhan O. COVID-19 pandemisi sırasında kronik lenfositik lösemi hastalarının yönetimi. Hematoloji ve COVID-19. 1.Baskı. Ankara: Türkiye Klinikleri; 2020.p.12-5.

Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Feb 29:ciaa199.

Mishra AK, Sahu KK, Lal A, Sargent J. Patterns of heart injury in COVID-19 and relation to outcome. J Med Virol. 2020 Apr 8.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337.

Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, et al. The outcome of COVID‐19 in patients with hematological malignancy. J Med Virol. 2021;93:1099–1104.

Gavillet M, Carr Klappert J, Spertini O, Blum S. Acute leukemia in the time of COVID-19. Leuk Res. 2020 Mar 26;92:106353.

Paul S, Rausch CR, Jain N, Kardia T, Ravandi F, DiNardo CD, et al. Treating leukemia in the time of COVID-19. Acta Haematol. 2020 May 11:1–13.

COVID-19 Lessons from Wuhan. Hematology.org [Internet]. [cited 2020 Jun 16].

Sahu KK, Cerny J. Managing patients with hematological malignancies during COVID-19 pandemic. Expert Revıew Of Hematology. 2020,vol.13,no.8,787–793.

Foà R, Bonifacio M, Chiaretti S, Curti A, Candoni A, Fava C, et al. Ph+ Acute Lymphoblastic Leukaemia in Italy During the Covid-19 Pandemic. A Campus ALL Study. Br J Haematol. 2020.

Yönal Hindilerden İ, Nalçacı M. COVID-19 ve miyelodisplastik sendrom. Hematoloji ve COVID-19. 1.Baskı. Ankara: Türkiye Klinikleri; 2020.p.37-42.

Mishra AK, Sahu KK, Kaul S, Lal A. Dasatinib induced pleuro-pericardial effusion. Acta Bio-Medica Atenei Parm. 2020 19;91(1):142–143.

Başcı S, Ata N, Altuntaş F, Yigenoglu TN, Dal MS, Kormaz S, et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm practice. 2020. 26(7),1676–1682.

15.Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, et al. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014 Jan; 99(1):140–147.

Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020 May 21;135(21):1912–1915.

COVID-19 and CLL: frequently asked questions. ASH COVID-19 Resources May 6,2020;version1.3.

Perini GF, Fisher T, Gaiolla RD, Rocha TB, Bellesso M, Teixeira LLC, et al. How to manage lymphoid malignancies during novel 2019 coronovirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell T her. 2020.

COVID-19 and Aggressive Lymphoma: frequently asked questions. ASH COVID-19 Resources. March 30, 2020; version1.0.

Ciaccio PD, McCaughan G, Trotman J, Ho PJ, CheahCY, Gangatharan S, et al. Australian and New Zealand consensusstate menton the management of lymphoma, chronic lymphocytic leukemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal. 2020;1-13.

American Society of Hematology. COVID-19 and Indolent Lymphomas: Frequently Asked Questions. April 13,2020. Version 2.0.

Büyüktaş D, Ferhanoğlu B. İndolen lenfomalar ve COVID-19 enfeksiyonu. Hematoloji ve COVID-19. 1.Baskı. Ankara: Türkiye Klinikleri;2020.p.5-7.

Hoppe RT, Advani R, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin lymphoma version1. 2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017.15(5):608-8.

Hematology, A.S.o, COVID-19 and Hodgkin Lymphoma: Frequently Asked Questions. 2020.

Lymphoma-action, Lymphoma treatment and COVID-19 for health care professionals. 2020.

CDC COVID-19 Response Team. Preliminary estimate sof the prevalence of selected underlying health conditions among patients with corona virus disease 2019 -United States, February 12 -March 28, 2020. Morbidity and Mortality Weekly Report. 2020.69(13):382.

Percival M, Lynch R, Halpern A, Shadman M, Cassaday R, Ujjani C, et al. Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. JCO Oncology Practice. 2020:OP.20.00241.

Barrington S, Kirkwood A, Franceschetto A, Fulham M, Roberts T, Almquist H, et al. PET-CT for staging and early response: results from the Response Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, The Journal of the American Society of Hematology. 2016.127(12):1531-8.

Connors JM. Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A +AVD) as front line therapy demonstrates superior modified progression free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): the phase 3 Echelon 1 study. Blood. 2017.130:6-6.

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi M, et al. Brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double blind, placebo controlled, phase 3 trial. The Lancet. 2015. 385(9980):1853-62.

http://thd.org.tr/ yayinlar/ list/ 77/ multipl miyelom tedavi kilavuzu.

Teh BW, Harrison SJ, Worth lJ, Spelman T, Thursky K, Slavin M. Risks, severity and timing of infections in patients with multiple myeloma: along itudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100-8.

Gökmen Sevindik Ö, Özsan GH. COVID-19 ve plazma hücre hastalıkları. Hematoloji ve COVID-19. 1.Baskı.Ankara: Türkiye Klinikleri;2020.p.43-7.

https://www.who.int/ emergencies/ diseases/ novel coronavirus-2019.

Onder G, Rezza G, Brusaferro S. Case Fatality Rate and Characteristics of patients Dying in Relation to COVID-19 in Italy. JAMA. 2020.

Willan J, King AJ, Hayes S, Collins G, Peniket A. Care of haematology patients in a COVID-19 epidemic. British Journal of Haematology. 2020;189,241-3.

American Society of Hematology. https://hematology.org/ covid-19/ covid-19 and myeloproliferative neoplasms.

Motta I, De Amicis MM, Pinto VM, Balocco M, Longo F, Bonetti F, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. American Journal of Hem. 2020 Apr 20.

Burnouf T, Conton B, Dye JM. Convalescent plasma for Ebola Virus disease. N Engl J Med. 2016;374(25):2499.

Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in HongKong. Eur J Clin. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.

Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, et al. Convalescent plasma therapy in patients with COVID-19. Transfusion and apheresis science, 102955. Advance online publication. https://doi.org/10.1016/j.transci.2020.102955

Yiğenoğlu TN, Hacıbekiroğlu T, Berber İ, Dal MS, Basturk A, Namdaroğlu S, et al. Convalescent plasma therapy in patients with COVID‐19. J Clin Apher. 2020;35:367–373.

Hacibekiroğlu T, Kalpakçı Y, Genç AC, Hacibekiroglu I, Sunu C, Saricaoglu A, et al. Efficacy of convalescent plasma according to blood groups in COVID-19 patients. Turk J Med Sci. 2020 Sep 20. doi:10.3906/sag-2007-59. Epub ahead of print. PMID: 32950044.